{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=129",
    "query": {
      "condition": "Immunity Disorders",
      "page": 129
    },
    "page_size": 10
  },
  "pagination": {
    "page": 129,
    "page_size": 10,
    "total_count": 21240,
    "total_pages": 2124,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=130&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=128&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T18:04:31.001Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02588651",
      "title": "A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T-cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Hepato-splenic T-cell Lymphoma",
        "Adult T-cell Leukemia/Lymphoma",
        "Enteropathy Associated T-cell Lymphoma",
        "NK T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Deepa Jagadeesh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2016-06-17",
      "completion_date": "2024-10-14",
      "has_results": true,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-11-12T18:04:31.001Z",
      "location_count": 4,
      "location_summary": "Detroit, Michigan • Hackensack, New Jersey • Cleveland, Ohio",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02588651"
    },
    {
      "nct_id": "NCT05369403",
      "title": "A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2022-12-19",
      "completion_date": "2025-02-05",
      "has_results": true,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-11-12T18:04:31.001Z",
      "location_count": 37,
      "location_summary": "Montgomery, Alabama • Phoenix, Arizona • Fountain Valley, California + 31 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Laguna Niguel",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05369403"
    },
    {
      "nct_id": "NCT01848327",
      "title": "Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Relapsing Remitting MS",
        "Secondary Progressive MS",
        "Primary Progressive MS"
      ],
      "interventions": [
        {
          "name": "Caprylic Triglyceride",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 124,
      "start_date": "2013-02",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-25",
      "last_synced_at": "2026-11-12T18:04:31.001Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848327"
    },
    {
      "nct_id": "NCT00000761",
      "title": "Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Interferon gamma-1b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 20,
      "start_date": null,
      "completion_date": "1997-10",
      "has_results": false,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-11-12T18:04:31.001Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000761"
    },
    {
      "nct_id": "NCT02264873",
      "title": "Phase I, Dose Escalation Study of Decitabine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Lymphoblastic, Acute",
        "Leukemia, Myeloid Acute",
        "Hematopoetic Myelodysplasia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 3,
      "start_date": "2014-10",
      "completion_date": "2018-09-18",
      "has_results": false,
      "last_update_posted_date": "2018-10-15",
      "last_synced_at": "2026-11-12T18:04:31.001Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02264873"
    },
    {
      "nct_id": "NCT01240694",
      "title": "A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "CEP-33457",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cephalon, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 136,
      "start_date": "2010-12-09",
      "completion_date": "2012-06-14",
      "has_results": true,
      "last_update_posted_date": "2022-12-30",
      "last_synced_at": "2026-11-12T18:04:31.001Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01240694"
    },
    {
      "nct_id": "NCT00060294",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "yttrium Y 90 ibritumomab tiuxetan",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-08",
      "last_synced_at": "2026-11-12T18:04:31.001Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00060294"
    },
    {
      "nct_id": "NCT03396822",
      "title": "Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Gadoteridol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-09-24",
      "completion_date": "2023-05-25",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-11-12T18:04:31.001Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03396822"
    },
    {
      "nct_id": "NCT01832922",
      "title": "BR in Patients With CLL With Comorbidities and/or Renal Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2013-04",
      "completion_date": "2016-11-28",
      "has_results": false,
      "last_update_posted_date": "2018-03-30",
      "last_synced_at": "2026-11-12T18:04:31.001Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01832922"
    },
    {
      "nct_id": "NCT04066205",
      "title": "Sleep Shared-Management Intervention for Children With Juvenile Idiopathic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Juvenile Idiopathic Arthritis"
      ],
      "interventions": [
        {
          "name": "SLEEPSAMRT",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "13 Years",
        "sex": "ALL",
        "summary": "8 Years to 13 Years"
      },
      "enrollment_count": 50,
      "start_date": "2019-11-01",
      "completion_date": "2021-05-20",
      "has_results": true,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-11-12T18:04:31.001Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04066205"
    }
  ]
}